Lisata Therapeutics (LSTA)

• Market cap: $22.9M
• 1 day: 1.10%
• 5 days: -4.18%
• 1 month: -7.72%
• 3 months: -7.09%
• 6 months: -2.48%
• Year to date: -1.08%
• 1 year: 20.09%
• 5 years: -1.43%
• 10 years: -93.65%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Employees: 25

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0.12% more ownership

Funds ownership: 9.08% [Q2] → 9.21% (+0.12%) [Q3]

9% less funds holding

Funds holding: 22 [Q2] → 20 (-2) [Q3]

12% less capital invested

Capital invested by funds: $2.62M [Q2] → $2.3M (-$323K) [Q3]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 445% upside
• Avg. target: $15 445% upside
• High target: $15 445% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 84 / 272 met price target

445% upside $15

Buy Reiterated

18 Sept 2024